fda glp-1 compounding enforcement news october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Dr. Elizabeth Kazarian, MD |
Description
Conclusions/interpretation Our findings do not support an increased risk of SIS when taking GLP-1RA in individuals with type 2 diabetes and obesity
Developed specifically to act as a pillar of support during phases of reduced food intake, this supplement actively serves to meet the body's micronutrient needs

But here's what's shocking In this ...

Experts weigh in on the rising trend of microdosing Ozempic and Wegovy.